US Patent

US11116721 — Pharmaceutical formulations comprising 4-{(1R)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl) phenol

Method of Use · Assigned to Glaxo Group Ltd · Expires 2029-02-26 · 3y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent provides novel pharmaceutical formulations of a beta-2 agonist for inhaled administration via the nose or mouth.

USPTO Abstract

Novel pharmaceutical formulations of a beta-2 agonist for inhaled administration via the nose or mouth, and methods of using them are provided.

Drugs covered by this patent

Arnuity Ellipta (FLUTICASONE FUROATE) · Haleon Us Holdings

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-1401`	—	Arnuity Ellipta
`U-3623`	—	Arnuity Ellipta
`U-3623`	—	Arnuity Ellipta

Patent Metadata

Patent number: US11116721
Jurisdiction: US
Classification: Method of Use
Expires: 2029-02-26
Drug substance claim: No
Drug product claim: Yes
Assignee: Glaxo Group Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.